Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
December 01, 2023 09:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Global Controlled Release Drug Delivery Market Analysis Report 2023-2030 - Growing Application of Non-Invasive Drug Delivery Techniques
November 28, 2023 07:53 ET
|
Research and Markets
Dublin, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Controlled Release Drug Delivery Market Size, Share & Industry Trends Analysis Report By Release Mechanism, By Technology, By Application,...
Cingulate to Host CNS Key Opinion Leader Panel in New York City
October 17, 2023 14:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Global Controlled Release Drugs Delivery Market Set to Exceed $100 Billion by 2029: Pharma Firms Embrace Innovations to Tackle Generic Competition
September 25, 2023 06:53 ET
|
Research and Markets
Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Pipeline Insight 2029" drug pipelines has been added to ...
Cingulate Inc. to Present at the LD Micro Main Event XVI
September 21, 2023 13:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $4.0 Million Public Offering
September 13, 2023 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Announces Pricing of $4.0 Million Public Offering
September 11, 2023 09:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary...
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
September 11, 2023 06:00 ET
|
Cingulate Inc.
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend...
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
September 08, 2023 16:31 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
SourceOne Global Partners celebrates 20-year anniversary, reflecting on pioneering a best-in-class high bioavailability technology platform
September 07, 2023 11:39 ET
|
SourceOne Global Partners
CHICAGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SourceOne Global Partners is proud to announce the launch of new, science-backed product solutions as it celebrates twenty years as a leading supplier to...